ASM Microbe

ASM Microbe

September 07, 2014
1 min read
Save

Patients with HCV, alcohol-use disorder had increased risk for liver-related mortality

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

WASHINGTON, D.C. — Patients with hepatitis C virus infection and alcohol-use disorder had an increased risk for mortality by liver-related causes compared with those with an alcohol-use disorder, but not hepatitis C virus, according to data presented at ICAAC 2014.

In a longitudinal study, researchers collected data and conducted tests, such as liver function tests, in 819 patients with alcohol-use disorder between 1999 and 2010 to determine if hepatitis C virus (HCV) infection played a role in causing mortality among patients receiving treatment for alcohol-use disorder. Among all the patients, 129 were positive for HCV, 690 patients were HCV-negative. The median follow-up was 3.8 years.

Of the patients with HCV, researchers found that 14.2% met standard criteria for alcohol-related liver disease. At admission, 81.6% of patients were male; average age was 44 years; average duration of alcohol-use disorder was 14 years; and the average daily intake of alcohol was 190 g.

When the study concluded, 11.6% of patients (n=95) had died. The main causes of mortality were liver-related illness (30%) (RR=3.80; 95% CI, 1.7-8.2), cancer (24%) (RR=0.55; 95% CI, 0.09-2.03) and cardiovascular events (14%) (RR=1.00; 95% CI, 0.15-4.04). More patients with HCV had died (4.1(2.6-6.1) compared with patients without HCV (2.5(1.9-3.1).    

“HCV infection in patients with [alcohol-use disorder] is associated with an increased risk of overall and liver-related mortality,” the researchers wrote. “The irruption of innovative anti-HCV therapies may have an impact in the survival of these patients.”

For more information:

Zuluaga P. Abstract V-480. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 5-9, 2014; Washington, D.C.

Disclosure: The researchers report no relevant financial disclosures.